This indicates that Kynamro is barely getting any traction with less than $10M of sales in 2013
$10M for Kynamro vs. $200M for Juxtapid?
I'm surprised Kynamro is even still for sale.
Kynamro is an intolerable drug (less than 50% compliance at one year) and has a poor cholesterol lowering activity. Juxtapid has an excellent tolerability, provided patients follow a strict diet, and superior activity. There is absolutely no match
Sentiment: Strong Buy
don't get happy REGN is entering the market soon.